CRMD CorMedix Inc.

QT44

Latest market price

5.70

-1.94-25.39%

Overview Short InterestFilings

CRMDQT44CorMedix Inc.·NASDAQ

Overview Short InterestFilings

5.70-25.39%

Loading chart...

Signal & projected range

QT Score downgradeHistorical pattern — not a prediction

Range still being built for this setupWe don’t yet have a frozen historical track record for qt score downgrade to describe a reliable spread of outcomes. The projected range appears once its backtest is established.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

TRAX-0.33%$45.08 NVAX-3.72%$10.08 NUVB-0.21%$4.76 KLRA-4.10%$12.86 REPL+1.27%$17.61 STOK-0.23%$26.29 QURE-1.86%$24.83 NTLA-5.74%$12.47

Snapshot

Index	—	P/E	2.68	EPS (ttm)	2.13	Insider Own	13.00%	Shs Outstand	77.94M	Perf Week	-27.39%

Market Cap	444.28M	Forward P/E	82.71	EPS next Y	0.07	Insider Trans	0.00%	Shs Float	65.89M	Perf Month	-23.18%

Enterprise Value	332.28M	PEG	0.10	EPS next Q	-0.10			Short Float	22.26%	Perf Quarter	-24.50%

Income	188.00M	P/S	0.96	EPS this Y	-81.52%			Short Ratio	13.15	Perf Half Y	-26.83%

Sales	462.00M	P/B	0.96	EPS next Y	-86.09%	ROA	20.70%	Short Interest	14.67M	Perf YTD	-50.99%

Book/sh	5.91	P/C	1.73	EPS next 5Y	27.76%	ROE	44.64%	52W High	13.02 -56.22%	Perf Year	-49.60%

Cash/sh	3.30	P/FCF	1.76	EPS past 3/5Y	—	ROIC	27.87%	52W Low	5.63 1.24%	Perf 3Y	86.89%

Dividend Est.	—	EV/EBITDA	1.33	Sales past 3/5Y	—	Gross Margin	82.78%	Volatility	9.96% 5.13%	Perf 5Y	20.00%

Dividend TTM	—	EV/Sales	0.72	EPS Y/Y TTM	182.94%	Oper. Margin	46.95%	ATR (14)	0.45	Perf 10Y	-49.56%

Dividend Ex-Date	—	Quick Ratio	2.36	Sales Y/Y TTM	281.82%	Profit Margin	40.49%	RSI (14)	25.30	Recom	2.00

Dividend Gr. 3/5Y	—	Current Ratio	2.56	EPS Q/Q	3.57%	SMA20	-23.82%	Beta	1.47	Target Price	15.00

Payout	0.00%	Debt/Eq	0.31	Sales Q/Q	155.00%	SMA50	-26.91%	Rel Volume	5.65	Prev Close	7.64

Employees	191	LT Debt/Eq	0.31	Earnings	Nov 11	SMA200	-25.71%	Avg Volume	1.24M	Price	5.70

IPO Date	May 13, 2010	Option/Short	Yes / Yes	EPS/Sales Surpr.	21.85% 6.13%	Net Debt/EBITDA	-0.45	Volume	7,002,015	Change	-25.39%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Sep-23-26	Initiated	Oppenheimer	Outperform	$15
Apr-28-26	Reiterated	RBC Capital	Outperform	$13 → $14
Mar-06-26	Reiterated	Leerink Partners		$13
Jan-23-26	Reiterated	HC Wainwright & Co.	Buy	$17 → $13
Jan-21-26	Reiterated	RBC Capital	Outperform	$22 → $13
Jan-08-26	Reiterated	Truist Financial	Buy	$20 → $16
Oct-21-25	Reiterated	RBC Capital	Outperform	$9.00 → $22
Oct-20-25	Upgrade	D. Boral Capital	Hold → Buy
Aug-08-25	Reiterated	HC Wainwright & Co.	Buy	$17
Jun-30-25	Downgrade	D. Boral Capital	Buy → Hold

Latest News· Times ET

Oct-22-26

Oct-22-2602:45AM

CorMedix (NASDAQ:CRMD) vs. MediciNova (NASDAQ:MNOV) Financial Analysisdefenseworld.net

Oct-19-26

Oct-19-2607:30AM

Cormedix Announces FDA Acceptance for Priority Review of Supplemental NDA for Rezzayo® (Rezafungin) for Prophylaxis of Invasive Fungal Diseasesglobenewswire.com

Oct-15-26

Oct-15-2607:30AM

Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial OfficerYahoo

Oct-08-26

Oct-08-2612:40PM

CRMD vs. PRTA: Which Stock Should Value Investors Buy Now?zacks.com

Sep-23-26

Sep-23-2602:31AM

Oppenheimer Initiates Coverage On Cormedix with Outperform Rating, Announces Price Target of $15Benzinga

Sep-07-26

Sep-07-2610:45PM

CorMedix (CRMD) Just Tripled Its Profits, But Guidance Barely BudgedYahoo

10:55AM

Wall Street Analysts Think CorMedix (CRMD) Could Surge 67.73%: Read This Before Placing a Betzacks.com

Sep-01-26

Sep-01-2608:30AM

CorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conferenceglobenewswire.com

Aug-31-26

Aug-31-2601:01PM

CorMedix (CRMD) Upgraded to Buy: Here's Whyzacks.com

Aug-20-26

Aug-20-2610:56AM

Wall Street Analysts Believe CorMedix (CRMD) Could Rally 65.96%: Here's is How to Tradezacks.com

Aug-18-26

Aug-18-2601:23AM

CorMedix: Durable Commercial Base, But 2027 Is The Real TestSeekingAlpha

Aug-14-26

Aug-14-2610:46AM

CRMD Stock Up as Q2 Earnings & Sales Beat on DefenCath, Melinta Gainszacks.com

07:26AM

RBC Capital Maintains Outperform on Cormedix, Raises Price Target to $14Benzinga

Aug-13-26

Aug-13-2601:47PM

CorMedix Inc. (CRMD) Q2 2026 Earnings Call Transcriptseekingalpha.com

11:07AM

CorMedix Q2 Earnings Call Highlightsmarketbeat.com

Company

CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	462	312	43	0	—	—	—	—	—
Cost of Goods Sold Incl. D&A	79	36	3	0	—	—	—	—	—
Gross Profit	382	276	40	0	—	—	—	—	—
Selling, General and Administrative Excl. Other	139	30	59	36	—	—	—	—	—
Research and Development	28	19	4	13	—	—	—	—	—
Other Operating Expense	-2	77	0	0	—	—	—	—	—
Operating Income	217	150	-22	-49	—	—	—	—	—
Interest Expense	3	3	0	0	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	-11	3	3	3	—	—	—	—	—
Net Income Before Taxes	204	150	-19	-46	—	—	—	—	—
Income Taxes	16	-13	-1	0	—	—	—	—	—
Consolidated Net Income	188	163	-18	-46	—	—	—	—	—
Net Income From Continuing Operations	188	163	-18	-46	—	—	—	—	—
Net Income	188	163	-18	-46	—	—	—	—	—
EPS (Recurring)	2.41	2.25	-0.30	-0.91	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	2.41	2.25	-0.30	-0.91	—	—	—	—	—
EPS (Diluted)	2.13	2.04	-0.30	-0.91	—	—	—	—	—
EBITDA	250	167	-19	-46	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	2.68	5.70	—	—	—	—	—	—	—
Price To Sales Ratio	0.96	2.68	11.11	—	—	—	—	—	—
Gross Margin	82.68	88.46	93.02	—	—	—	—	—	—
Operating Margin	46.97	48.08	-51.16	—	—	—	—	—	—
Net Margin	40.69	52.24	-41.86	—	—	—	—	—	—
Shares Outstanding	78	72	59	51	—	—	—	—	—
Market Capitalization	445	837	478	192	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dillione Janet	Director	Sep 18 '26	Option Exercise	0.00	48,909	0	117,835	Sep 18
Dillione Janet	Director	Jan 21 '26	Sale	6.88	10,000	68,800	38,473	Jan 22
Todisco Joseph	Chief Executive Officer	Jan 16 '26	Option Exercise	3.38	29,585	99,997	521,664	Jan 20
Lefkowitz Steven W	Director	Jan 12 '26	Option Exercise	5.63	15,000	84,450	95,498	Jan 14
DUNTON ALAN W	Director	Dec 30 '25	Option Exercise	4.03	20,000	80,600	60,250	Jan 02
DUNTON ALAN W	Director	Dec 30 '25	Sale	13.00	20,000	260,000	40,250	Jan 02
Todisco Joseph	Chief Executive Officer	Dec 18 '25	Option Exercise	4.43	30,000	132,900	539,496	Dec 19
Todisco Joseph	Chief Executive Officer	Dec 18 '25	Sale	12.00	30,000	360,000	509,496	Dec 19
Dillione Janet	Director	Dec 09 '25	Option Exercise	7.82	34,000	265,900	82,473	Dec 11
Dillione Janet	Director	Dec 09 '25	Sale	12.00	34,000	408,000	48,473	Dec 11
Lefkowitz Steven W	Director	Dec 09 '25	Sale	11.88	40,000	475,200	80,498	Dec 10
Dillione Janet	Director	Dec 02 '25	Option Exercise	3.96	46,657	184,802	95,130	Dec 04
Dillione Janet	Director	Dec 02 '25	Sale	10.00	46,657	466,570	48,473	Dec 04
Dillione Janet	Director	Nov 24 '25	Option Exercise	3.64	26,343	95,948	74,816	Nov 26
Dillione Janet	Director	Nov 24 '25	Sale	9.93	26,343	261,586	48,473	Nov 26

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.